ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.3454G>A (p.Asp1152Asn) (rs80357175)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 16
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001081256 SCV000076216 likely benign Hereditary breast and ovarian cancer syndrome 2019-12-31 criteria provided, single submitter clinical testing
Ambry Genetics RCV000129496 SCV000184268 likely benign Hereditary cancer-predisposing syndrome 2019-01-03 criteria provided, single submitter clinical testing Co-occurence with mutation in same gene (phase unknown);Intact protein function observed in appropriate functional assay(s);In silico models in agreement (benign)
GeneDx RCV000589160 SCV000210147 uncertain significance not provided 2017-09-29 criteria provided, single submitter clinical testing This variant is denoted BRCA1 c.3454G>A at the cDNA level, p.Asp1152Asn (D1152N) at the protein level, and results in the change of an Aspartic Acid to an Asparagine (GAC>AAC). Using alternate nomenclature, this variant would be defined as BRCA1 3573G>A. This variant has been identified in individuals with a personal and/or family history of breast and/or ovarian cancer, as well as in a pediatric patient with leukemia (Hansen 2009, Borg 2010, Stegel 2011, Kluska 2015, Zhang 2015, Dos Santos Vidal 2016). An in vitro-based homology-directed repair (HDR) assay showed this variant to exhibit HDR activity comparable to wildtype (Lu 2015). BRCA1 Asp1152Asn was not observed at a significant allele frequency in large population cohorts (Lek 2016). Since Aspartic Acid and Asparagine differ in some properties, this is considered a semi-conservative amino acid substitution. BRCA1 Asp1152Asn occurs at a position that is not conserved and is not located in a known functional domain. In silico analyses predict that this variant is probably damaging to protein structure and function. Based on currently available evidence, it is unclear whether BRCA1 Asp1152Asn is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Department of Pathology and Molecular Medicine,Queen's University RCV000212174 SCV000588045 uncertain significance not specified 2017-04-20 criteria provided, single submitter clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000212174 SCV000591448 uncertain significance not specified 2016-02-10 criteria provided, single submitter clinical testing
Genetic Services Laboratory,University of Chicago RCV000212174 SCV000593681 uncertain significance not specified 2016-09-29 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000212174 SCV000600334 uncertain significance not specified 2017-01-21 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000589160 SCV000699034 likely benign not provided 2017-07-28 criteria provided, single submitter clinical testing Variant summary: The BRCA1 c.3454G>A (p.Asp1152Asn) variant involves the alteration of a conserved nucleotide. 4/4 in silico tools predict a benign outcome for this variant (SNPsandGO not captured due to low reliability index) (BP4). This variant was found in 2/121394 control chromosomes at a frequency of 0.0000165, which does not exceed the estimated maximal expected allele frequency of a pathogenic BRCA1 variant (0.0010005). This variant has been reported in multiple affected individuals without strong evidence for causality. The HDR assay showed the variant with relative HDR activity of 1.7306 (WT=1; Lu_2015) (ACMG criteria BS3). One individual reported in UMD also carried a likely pathogenic variant in BRCA1 c.4485_4675del/p.Ser1496GlyfsX14, further supporting benign nature of this variant (ACMG criteria BP2). Multiple clinical diagnostic laboratories/reputable databases classified this variant as uncertain significance, and one classified it as benign, all without evidence for independent evaluation. Taken together, and considering the ACMG guidelines, this variant is classified as likely benign until more evidence becomes available.
PreventionGenetics,PreventionGenetics RCV000589160 SCV000806934 uncertain significance not provided 2017-08-18 criteria provided, single submitter clinical testing
Color RCV000129496 SCV000902880 likely benign Hereditary cancer-predisposing syndrome 2015-04-28 criteria provided, single submitter clinical testing
CeGaT Praxis fuer Humangenetik Tuebingen RCV000589160 SCV001151331 uncertain significance not provided 2019-03-01 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000212174 SCV001160216 uncertain significance not specified 2019-01-09 criteria provided, single submitter clinical testing The BRCA1 c.3454G>A; p.Asp1152Asn variant (rs80357175), also known as 3573G>A in traditional nomenclature, is reported in the literature in multiple individuals affected with breast and/or ovarian cancer, as well as one pediatric patient with leukemia (Borg 2010, Kluska 2015, Stegel 2011, Zhang 2015). This variant is reported as uncertain significance by multiple laboratories in ClinVar (Variation ID: 54890), and is found in the non-Finnish European population with an allele frequency of 0.0085% (11/129,078 alleles) in the Genome Aggregation Database. The aspartic acid at codon 1152 is moderately conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is tolerated. In vitro functional analyses demonstrate activity similar to wildtype in a homology-directed repair assay (Lu 2015). Due to limited information, the clinical significance of the p.Asp1152Asn variant is uncertain at this time. References: Borg A et al. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat. 2010 Mar;31(3):E1200-40. Kluska A et al. New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing. BMC Med Genomics. 2015 May 7;8:19. Lu C et al. Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun. 2015 Dec 22;6:10086. Stegel V et al. The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population. BMC Med Genet. 2011 Jan 14;12:9. Zhang J et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med. 2015 Dec 10;373(24):2336-2346.
Centre for Mendelian Genomics,University Medical Centre Ljubljana RCV001196675 SCV001367306 uncertain significance Hereditary Cancer Syndrome 2019-09-16 criteria provided, single submitter clinical testing This variant was classified as: Uncertain significance. The available evidence on this varinat's pathogenicity is insufficient or conflicting. The following ACMG criteria were applied in classifying this variant: PP3. This variant was detected in heterozygous state.
Breast Cancer Information Core (BIC) (BRCA1) RCV000112100 SCV000144768 uncertain significance Breast-ovarian cancer, familial 1 2004-02-20 no assertion criteria provided clinical testing
Sharing Clinical Reports Project (SCRP) RCV000112100 SCV000297600 benign Breast-ovarian cancer, familial 1 2010-01-14 no assertion criteria provided clinical testing
MVZ Praenatalmedizin und Genetik Nuernberg RCV000112100 SCV000777893 uncertain significance Breast-ovarian cancer, familial 1 2018-05-01 no assertion criteria provided clinical testing This rare variant (gnomAD) was found multiple times in databases and literature with uncertain significance. In silico analyses show contradictory results. Therefore we rate this variant as Variant of unknown significance (VUS). Interestingly we found this variant in a patient who harbored also a pathogenic BRCA2-variant (NM_000059.3|c.5238dupT|het)

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.